An Yoshimori, Ando Kenji, Soga Yoshimitsu, Nomura Akihiro, Nagashima Michio, Hayashi Kentaro, Makihara Yu, Fukunaga Masato, Hiroshima Ken-Ichi, Nobuyoshi Masakiyo, Goya Masahiko
Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
J Arrhythm. 2017 Feb;33(1):17-22. doi: 10.1016/j.joa.2016.01.012. Epub 2016 Jun 28.
Data regarding long-term mortality and factors influencing appropriate therapies in Japanese patients with implantable cardioverter defibrillators (ICD), who satisfy the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) criteria for primary prevention, remain scarce.
A total of 118 consecutive patients who underwent ICD implantation without any prior ventricular arrhythmic event, from January 2000 to December 2012, were enrolled based on the MADIT II criteria: left ventricular ejection fraction (LVEF) of ≤30% with ischemic heart disease and at least 4 weeks after a myocardial infarction. We investigated the mortality and factors influencing appropriate ICD therapies in this population.
The mean age was 69±10 years, and the mean LVEF was 25.1±4.5%. During the median follow up of 1406 days, the mortality rate was 20%, and the incidence of appropriate ICD therapy was 37% at 3 years. Multivariate analysis by using Cox regression model showed that left ventricular diastolic diameter ≥60 mm (hazard ratio [HR], 2.31; 95% confidence interval [CI], 1.07-5.38; =0.033) and the presence of non-sustained ventricular tachycardia (NSVT) before implantation (HR, 2.26; 95% CI, 1.17-4.39; =0.015) were independent predictors of appropriate ICD therapy.
The mortality and incidence of appropriate ICD therapy were 20% and 37%, respectively, at 3 years in Japanese patients who met the MADIT II criteria during ICD implantation for primary prevention of sudden cardiac death. The presence of NSVT and dilated left ventricle independently predicted the incidence of appropriate ICD therapy after implantation.
对于符合多中心自动除颤器植入试验II(MADIT II)一级预防标准的植入式心脏复律除颤器(ICD)日本患者,关于长期死亡率及影响恰当治疗的因素的数据仍然匮乏。
2000年1月至2012年12月期间,共有118例既往无室性心律失常事件且接受ICD植入的连续患者,基于MADIT II标准入组:缺血性心脏病患者左心室射血分数(LVEF)≤30%,且心肌梗死后至少4周。我们调查了该人群的死亡率及影响恰当ICD治疗的因素。
平均年龄为69±10岁,平均LVEF为25.1±4.5%。在1406天的中位随访期内,死亡率为20%,3年时恰当ICD治疗的发生率为37%。使用Cox回归模型进行多变量分析显示,左心室舒张直径≥60 mm(风险比[HR],2.31;95%置信区间[CI],1.07 - 5.38;P = 0.033)以及植入前存在非持续性室性心动过速(NSVT)(HR,2.26;95% CI,1.17 - 4.39;P = 0.015)是恰当ICD治疗的独立预测因素。
在因心脏性猝死一级预防而植入ICD期间符合MADIT II标准的日本患者中,3年时死亡率和恰当ICD治疗的发生率分别为20%和37%。NSVT的存在和左心室扩大独立预测了植入后恰当ICD治疗的发生率。